Shares of Protagonist Therapeutics, Inc. (PTGX) are falling more than 8% Wednesday morning after the company priced its previously-announced public offering of 5 million shares at $20 per share.
The company expects gross proceeds of about $100 million from the offering, which is expected to close on or about April 10.
Protagonist plans to use the net proceeds to fund its clinical development and pre-commercialization activities associated with rusfertide and for working capital and general corporate purposes.
PTGX is at $19.80 currently. It has traded in the range of $6.91-$25.76 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
